Review Article

SGLT-2抑制剂:2型糖尿病的新一代治疗方法

卷 31, 期 30, 2024

发表于: 19 October, 2023

页: [4781 - 4806] 页: 26

弟呕挨: 10.2174/0109298673251493231011192520

价格: $65

Open Access Journals Promotions 2
摘要

近年来,2型糖尿病(T2DM)已成为全球关注的问题,主要发生在高度发达的西方社会。T2DM可引起全身并发症,如动脉粥样硬化性心脏病、缺血性中风、外周动脉疾病、肾衰竭、糖尿病相关黄斑病变和视网膜病变。不断增长的T2DM患者数量和长期T2DM相关并发症的治疗给公共卫生系统带来了压力和压力。因此,防治2型糖尿病和开发新药的战略是至关重要的全球公共卫生要求。预防措施仍然是预防2型糖尿病最有效的方法,除此之外,新的和高效的治疗方法正在出现。在下一代T2DM治疗的聚光灯下,钠-葡萄糖共转运蛋白2 (SGLT-2)抑制剂被认为是最有效的透视治疗方法。SGLT-2抑制剂(SGLT2i)包括苯连菌素衍生物,如卡格列净、达格列净、恩格列净和埃图格列净。SGLT-2和SGLT-1是SGLT蛋白家族的成员,通过Na+/K+ atp酶介导的主动转运在葡萄糖吸收中发挥作用。SGLT-2仅存在于肾脏,特别是近端小管中,负责90%以上的葡萄糖吸收。抑制SGLT-2减少葡萄糖吸收,从而增加尿糖排泄,降低血糖水平。因此,抑制SGLT-2活性最终可缓解t2dm相关症状,预防或延缓t2dm相关的全身慢性并发症。本综述旨在更详细地了解SGLT2i对血糖调节的作用,这是控制t2dm相关心血管并发症的先决条件。

关键词: 2型糖尿病,T2DM,钠-葡萄糖转运蛋白,SGLT-2抑制剂,心血管并发症,糖尿病。

[1]
Liu, J.; Ren, Z.H.; Qiang, H.; Wu, J.; Shen, M.; Zhang, L.; Lyu, J. Trends in the incidence of diabetes mellitus: Results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health, 2020, 20(1), 1415.
[http://dx.doi.org/10.1186/s12889-020-09502-x] [PMID: 32943028]
[2]
Khan, M.A.B.; Hashim, M.J.; King, J.K.; Govender, R.D.; Mustafa, H.; Al Kaabi, J. Epidemiology of type 2 diabetes – Global burden of disease and forecasted trends. J. Epidemiol. Glob. Health, 2019, 10(1), 107-111.
[http://dx.doi.org/10.2991/jegh.k.191028.001] [PMID: 32175717]
[3]
Baxter, A.J.; Coyne, T.; McClintock, C. Dietary patterns and metabolic syndrome-a review of epidemiologic evidence. Asia Pac. J. Clin. Nutr., 2006, 15(2), 134-142.
[PMID: 16672196]
[4]
Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; Pavkov, M.E.; Ramachandaran, A.; Wild, S.H.; James, S.; Herman, W.H.; Zhang, P.; Bommer, C.; Kuo, S.; Boyko, E.J.; Magliano, D.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract., 2022, 183, 109119.
[http://dx.doi.org/10.1016/j.diabres.2021.109119] [PMID: 34879977]
[5]
Dieleman, J.L.; Baral, R.; Birger, M.; Bui, A.L.; Bulchis, A.; Chapin, A.; Hamavid, H.; Horst, C.; Johnson, E.K.; Joseph, J.; Lavado, R.; Lomsadze, L.; Reynolds, A.; Squires, E.; Campbell, M.; DeCenso, B.; Dicker, D.; Flaxman, A.D.; Gabert, R.; Highfill, T.; Naghavi, M.; Nightingale, N.; Templin, T.; Tobias, M.I.; Vos, T.; Murray, C.J.L. US spending on personal health care and public health, 1996-2013. JAMA, 2016, 316(24), 2627-2646.
[http://dx.doi.org/10.1001/jama.2016.16885] [PMID: 28027366]
[6]
Galicia-Garcia, U.; Benito-Vicente, A.; Jebari, S.; Larrea-Sebal, A.; Siddiqi, H.; Uribe, K.B.; Ostolaza, H.; Martín, C. Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 2020, 21, 17.
[7]
Cryer, P.E. Hypoglycemia, functional brain failure, and brain death. J. Clin. Invest., 2007, 117(4), 868-870.
[http://dx.doi.org/10.1172/JCI31669] [PMID: 17404614]
[8]
Cui, Y.; Wang, Y.; Liu, M.; Qiu, L.; Xing, P.; Wang, X.; Ying, G.; Li, B. Determination of glucose deficiency-induced cell death by mitochondrial ATP generation-driven proton homeostasis. J. Mol. Cell Biol., 2017, 9(5), 395-408.
[http://dx.doi.org/10.1093/jmcb/mjx011] [PMID: 28369514]
[9]
Kawahito, S.; Kitahata, H.; Oshita, S. Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress. World J. Gastroenterol., 2009, 15(33), 4137-4142.
[http://dx.doi.org/10.3748/wjg.15.4137] [PMID: 19725147]
[10]
Macdonald, I.A. A review of recent evidence relating to sugars, insulin resistance and diabetes. Eur. J. Nutr., 2016, 55(S2), 17-23.
[http://dx.doi.org/10.1007/s00394-016-1340-8] [PMID: 27882410]
[11]
Gromova, L.V.; Fetissov, S.O. Mechanisms of glucose absorption in the small intestine in health and metabolic diseases and their role in appetite regulation. Nutrients, 2021, 13(7), 2474.
[12]
Adeva-Andany, M.M.; Pérez-Felpete, N.; Fernández-Fernández, C.; Donapetry-García, C.; Pazos-García, C. Liver glucose metabolism in humans. Biosci. Rep., 2016, 36(6), e00416.
[http://dx.doi.org/10.1042/BSR20160385] [PMID: 27707936]
[13]
Sambuceti, G.; Cossu, V.; Bauckneht, M.; Morbelli, S.; Orengo, A.; Carta, S.; Ravera, S.; Bruno, S.; Marini, C. 18F-fluoro-2-deoxy-d-glucose (FDG) uptake. What are we looking at? Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(5), 1278-1286.
[http://dx.doi.org/10.1007/s00259-021-05368-2] [PMID: 33864142]
[14]
Wood, I.S.; Trayhurn, P. Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br. J. Nutr., 2003, 89(1), 3-9.
[http://dx.doi.org/10.1079/BJN2002763] [PMID: 12568659]
[15]
Navale, A.M.; Paranjape, A.N. Glucose transporters: Physiological and pathological roles. Biophys. Rev., 2016, 8(1), 5-9.
[http://dx.doi.org/10.1007/s12551-015-0186-2] [PMID: 28510148]
[16]
Chadt, A.; Al-Hasani, H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch., 2020, 472(9), 1273-1298.
[http://dx.doi.org/10.1007/s00424-020-02417-x] [PMID: 32591906]
[17]
Wright, E.M. Renal Na+-glucose cotransporters. Am. J. Physiol. Renal Physiol., 2001, 280(1), F10-F18.
[http://dx.doi.org/10.1152/ajprenal.2001.280.1.F10] [PMID: 11133510]
[18]
Joost, H.G.; Thorens, B. The extended GLUT-family of sugar/polyol transport facilitators: Nomenclature, sequence characteristics, and potential function of its novel members. Mol. Membr. Biol., 2001, 18(4), 247-256.
[http://dx.doi.org/10.1080/09687680110090456] [PMID: 11780753]
[19]
Pizzagalli, M.D.; Bensimon, A.; Superti-Furga, G. A guide to plasma membrane solute carrier proteins. FEBS J., 2021, 288(9), 2784-2835.
[http://dx.doi.org/10.1111/febs.15531]
[20]
Scheepers, A.; Joost, H.G.; Schürmann, A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. JPEN J. Parenter. Enteral Nutr., 2004, 28(5), 364-371.
[http://dx.doi.org/10.1177/0148607104028005364] [PMID: 15449578]
[21]
Schmidt, A.M. Diabetes mellitus and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2019, 39(4), 558-568.
[http://dx.doi.org/10.1161/ATVBAHA.119.310961] [PMID: 30786741]
[22]
Zaric, B.; Obradovic, M.; Trpkovic, A.; Banach, M.; Mikhailidis, D.P.; Isenovic, E.R. Endothelial dysfunction in dyslipidaemia: Molecular mechanisms and clinical implications. Curr. Med. Chem., 2020, 27(7), 1021-1040.
[http://dx.doi.org/10.2174/0929867326666190903112146] [PMID: 31480995]
[23]
Stanimirovic, J.; Radovanovic, J. Role of C-reactive protein in diabetic inflammation. Mediators Inflamm., 2022, 2022, 3706508.
[24]
Blendea, M.C.; McFarlane, S.I.; Isenovic, E.R.; Gick, G.; Sowers, J.R. Heart disease in diabetic patients. Curr. Diab. Rep., 2003, 3(3), 223-229.
[http://dx.doi.org/10.1007/s11892-003-0068-z] [PMID: 12762970]
[25]
Suzuki, K.; Nakagawa, K.; Miyazawa, T. Augmentation of blood lipid glycation and lipid oxidation in diabetic patients. Clin. Chem. Lab. Med., 2014, 52(1), 47-52.
[http://dx.doi.org/10.1515/cclm-2012-0886] [PMID: 23454716]
[26]
Gluvic, Z.; Zaric, B.; Resanovic, I.; Obradovic, M.; Mitrovic, A.; Radak, D.; Isenovic, E. Link between metabolic syndrome and insulin resistance. Curr. Vasc. Pharmacol., 2016, 15(1), 30-39.
[http://dx.doi.org/10.2174/1570161114666161007164510] [PMID: 27748199]
[27]
Zaric, B.L.; Radovanovic, J.N.; Gluvic, Z.; Stewart, A.J.; Essack, M.; Motwalli, O.; Gojobori, T.; Isenovic, E.R. Atherosclerosis linked to aberrant amino acid metabolism and immunosuppressive amino acid catabolizing enzymes. Front. Immunol., 2020, 11, 551758.
[http://dx.doi.org/10.3389/fimmu.2020.551758] [PMID: 33117340]
[28]
Yamagishi, S.; Matsui, T. Role of hyperglycemia-induced advanced glycation end product (AGE) accumulation in atherosclerosis. Ann. Vasc. Dis., 2018, 11(3), 253-258.
[http://dx.doi.org/10.3400/avd.ra.18-00070] [PMID: 30402172]
[29]
Sudar-Milovanovic, E.; Gluvic, Z.; Obradovic, M.; Zaric, B.; Isenovic, E.R. Tryptophan metabolism in atherosclerosis and diabetes. Curr. Med. Chem., 2022, 29(1), 99-113.
[http://dx.doi.org/10.2174/0929867328666210714153649] [PMID: 34269660]
[30]
López-Díez, R.; Egaña-Gorroño, L.; Senatus, L.; Shekhtman, A.; Ramasamy, R.; Schmidt, A.M. Diabetes and cardiovascular complications: The epidemics continue. Curr. Cardiol. Rep., 2021, 23(7), 74.
[http://dx.doi.org/10.1007/s11886-021-01504-4] [PMID: 34081211]
[31]
Veljkovic, N.; Zaric, B.; Djuric, I.; Obradovic, M. Genetic markers for coronary artery disease. Medicina, 2018, 54(3), 36.
[32]
Macvanin, M.T.; Rizzo, M. Role of chemerin in cardiovascular diseases. Biomedicines, 2022, 10(11), 2970.
[http://dx.doi.org/10.3390/biomedicines10112970]
[33]
Macvanin, M.; Obradovic, M.; Zafirovic, S.; Stanimirovic, J.; Isenovic, E.R. The role of miRNAs in metabolic diseases. Curr. Med. Chem., 2022, 30(17), 1922-1944.
[PMID: 35927902]
[34]
Dal Canto, E.; Ceriello, A.; Rydén, L.; Ferrini, M.; Hansen, T.B.; Schnell, O.; Standl, E.; Beulens, J.W.J. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol., 2019, 26(2_suppl), 25-32.
[http://dx.doi.org/10.1177/2047487319878371] [PMID: 31722562]
[35]
Miller, R.G.; Costacou, T. Risk factor modeling for cardiovascular disease in type 1 diabetes in the pittsburgh epidemiology of diabetes complications (edc) study: A comparison with the diabetes control and complications trial/epidemiology of diabetes interventions and complications study (DCCT/EDIC). Diabetes, 2019, 68(2), 409-419.
[36]
Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Eur. Heart J., 2013, 34(31), 2436-2443.
[http://dx.doi.org/10.1093/eurheartj/eht149] [PMID: 23641007]
[37]
Rawshani, A.; Rawshani, A.; Franzén, S.; Sattar, N.; Eliasson, B.; Svensson, A.M.; Zethelius, B.; Miftaraj, M.; McGuire, D.K.; Rosengren, A.; Gudbjörnsdottir, S. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2018, 379(7), 633-644.
[http://dx.doi.org/10.1056/NEJMoa1800256] [PMID: 30110583]
[38]
Caussy, C.; Aubin, A.; Loomba, R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr. Diab. Rep., 2021, 21(5), 15.
[http://dx.doi.org/10.1007/s11892-021-01383-7] [PMID: 33742318]
[39]
Xu, Q.; Wei, Y.; Fan, S.; Wang, L.; Zhou, X. Repetitive hyperbaric oxygen treatment increases insulin sensitivity in diabetes patients with acute intracerebral hemorrhage. Neuropsychiatr. Dis. Treat., 2017, 13, 421-426.
[http://dx.doi.org/10.2147/NDT.S126288] [PMID: 28228657]
[40]
Roth, G.A.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; Abdollahpour, I.; Abdulkader, R.S.; Abebe, H.T.; Abebe, M.; Abebe, Z.; Abejie, A.N.; Abera, S.F.; Abil, O.Z.; Abraha, H.N.; Abrham, A.R.; Abu-Raddad, L.J.; Accrombessi, M.M.K.; Acharya, D.; Adamu, A.A.; Adebayo, O.M.; Adedoyin, R.A.; Adekanmbi, V.; Adetokunboh, O.O.; Adhena, B.M.; Adib, M.G.; Admasie, A.; Afshin, A.; Agarwal, G.; Agesa, K.M.; Agrawal, A.; Agrawal, S.; Ahmadi, A.; Ahmadi, M.; Ahmed, M.B.; Ahmed, S.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akbari, M.E.; Akinyemi, R.O.; Akseer, N.; Al-Aly, Z.; Al-Eyadhy, A.; Al-Raddadi, R.M.; Alahdab, F.; Alam, K.; Alam, T.; Alebel, A.; Alene, K.A.; Alijanzadeh, M.; Alizadeh-Navaei, R.; Aljunid, S.M.; Alkerwi, A.; Alla, F.; Allebeck, P.; Alonso, J.; Altirkawi, K.; Alvis-Guzman, N.; Amare, A.T.; Aminde, L.N.; Amini, E.; Ammar, W.; Amoako, Y.A.; Anber, N.H.; Andrei, C.L.; Androudi, S.; Animut, M.D.; Anjomshoa, M.; Ansari, H.; Ansha, M.G.; Antonio, C.A.T.; Anwari, P.; Aremu, O.; Ärnlöv, J.; Arora, A.; Arora, M.; Artaman, A.; Aryal, K.K.; Asayesh, H.; Asfaw, E.T.; Ataro, Z.; Atique, S.; Atre, S.R.; Ausloos, M.; Avokpaho, E.F.G.A.; Awasthi, A.; Quintanilla, B.P.A.; Ayele, Y.; Ayer, R.; Azzopardi, P.S.; Babazadeh, A.; Bacha, U.; Badali, H.; Badawi, A.; Bali, A.G.; Ballesteros, K.E.; Banach, M.; Banerjee, K.; Bannick, M.S.; Banoub, J.A.M.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Barquera, S.; Barrero, L.H.; Bassat, Q.; Basu, S.; Baune, B.T.; Baynes, H.W.; Bazargan-Hejazi, S.; Bedi, N.; Beghi, E.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Bekele, B.B.; Belachew, A.B.; Belay, E.; Belay, Y.A.; Bell, M.L.; Bello, A.K.; Bennett, D.A.; Bensenor, I.M.; Berman, A.E.; Bernabe, E.; Bernstein, R.S.; Bertolacci, G.J.; Beuran, M.; Beyranvand, T.; Bhalla, A.; Bhattarai, S.; Bhaumik, S.; Bhutta, Z.A.; Biadgo, B.; Biehl, M.H.; Bijani, A.; Bikbov, B.; Bilano, V.; Bililign, N.; Bin Sayeed, M.S.; Bisanzio, D.; Biswas, T.; Blacker, B.F.; Basara, B.B.; Borschmann, R.; Bosetti, C.; Bozorgmehr, K.; Brady, O.J.; Brant, L.C.; Brayne, C.; Brazinova, A.; Breitborde, N.J.K.; Brenner, H.; Briant, P.S.; Britton, G.; Brugha, T.; Busse, R.; Butt, Z.A.; Callender, C.S.K.H.; Campos-Nonato, I.R.; Campuzano Rincon, J.C.; Cano, J.; Car, M.; Cárdenas, R.; Carreras, G.; Carrero, J.J.; Carter, A.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castillo Rivas, J.; Castle, C.D.; Castro, C.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chang, J-C.; Charlson, F.J.; Chaturvedi, P.; Chiang, P.P-C.; Chimed-Ochir, O.; Chisumpa, V.H.; Chitheer, A.; Chowdhury, R.; Christensen, H.; Christopher, D.J.; Chung, S-C.; Cicuttini, F.M.; Ciobanu, L.G.; Cirillo, M.; Cohen, A.J.; Cooper, L.T.; Cortesi, P.A.; Cortinovis, M.; Cousin, E.; Cowie, B.C.; Criqui, M.H.; Cromwell, E.A.; Crowe, C.S.; Crump, J.A.; Cunningham, M.; Daba, A.K.; Dadi, A.F.; Dandona, L.; Dandona, R.; Dang, A.K.; Dargan, P.I.; Daryani, A.; Das, S.K.; Gupta, R.D.; Neves, J.D.; Dasa, T.T.; Dash, A.P.; Davis, A.C.; Davis Weaver, N.; Davitoiu, D.V.; Davletov, K.; De La Hoz, F.P.; De Neve, J-W.; Degefa, M.G.; Degenhardt, L.; Degfie, T.T.; Deiparine, S.; Demoz, G.T.; Demtsu, B.B.; Denova-Gutiérrez, E.; Deribe, K.; Dervenis, N.; Des Jarlais, D.C.; Dessie, G.A.; Dey, S.; Dharmaratne, S.D.; Dicker, D.; Dinberu, M.T.; Ding, E.L.; Dirac, M.A.; Djalalinia, S.; Dokova, K.; Doku, D.T.; Donnelly, C.A.; Dorsey, E.R.; Doshi, P.P.; Douwes-Schultz, D.; Doyle, K.E.; Driscoll, T.R.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Duncan, B.B.; Duraes, A.R.; Ebrahimi, H.; Ebrahimpour, S.; Edessa, D.; Edvardsson, D.; Eggen, A.E.; El Bcheraoui, C.; El Sayed Zaki, M.; El-Khatib, Z.; Elkout, H.; Ellingsen, C.L.; Endres, M.; Endries, A.Y.; Er, B.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esmaeili, R.; Esteghamati, A.; Fakhar, M.; Fakhim, H.; Faramarzi, M.; Fareed, M.; Farhadi, F.; Farinha, C.S.E.; Faro, A.; Farvid, M.S.; Farzadfar, F.; Farzaei, M.H.; Feigin, V.L.; Feigl, A.B.; Fentahun, N.; Fereshtehnejad, S-M.; Fernandes, E.; Fernandes, J.C.; Ferrari, A.J.; Feyissa, G.T.; Filip, I.; Finegold, S.; Fischer, F.; Fitzmaurice, C.; Foigt, N.A.; Foreman, K.J.; Fornari, C.; Frank, T.D.; Fukumoto, T.; Fuller, J.E.; Fullman, N.; Fürst, T.; Furtado, J.M.; Futran, N.D.; Gallus, S.; Garcia-Basteiro, A.L.; Garcia-Gordillo, M.A.; Gardner, W.M.; Gebre, A.K.; Gebrehiwot, T.T.; Gebremedhin, A.T.; Gebremichael, B.; Gebremichael, T.G.; Gelano, T.F.; Geleijnse, J.M.; Genova-Maleras, R.; Geramo, Y.C.D.; Gething, P.W.; Gezae, K.E.; Ghadami, M.R.; Ghadimi, R.; Ghasemi Falavarjani, K.; Ghasemi-Kasman, M.; Ghimire, M.; Gibney, K.B.; Gill, P.S.; Gill, T.K.; Gillum, R.F.; Ginawi, I.A.; Giroud, M.; Giussani, G.; Goenka, S.; Goldberg, E.M.; Goli, S.; Gómez-Dantés, H.; Gona, P.N.; Gopalani, S.V.; Gorman, T.M.; Goto, A.; Goulart, A.C.; Gnedovskaya, E.V.; Grada, A.; Grosso, G.; Gugnani, H.C.; Guimaraes, A.L.S.; Guo, Y.; Gupta, P.C.; Gupta, R.; Gupta, R.; Gupta, T.; Gutiérrez, R.A.; Gyawali, B.; Haagsma, J.A.; Hafezi-Nejad, N.; Hagos, T.B.; Hailegiyorgis, T.T.; Hailu, G.B.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Handal, A.J.; Hankey, G.J.; Harb, H.L.; Harikrishnan, S.; Haro, J.M.; Hasan, M.; Hassankhani, H.; Hassen, H.Y.; Havmoeller, R.; Hay, R.J.; Hay, S.I.; He, Y.; Hedayatizadeh-Omran, A.; Hegazy, M.I.; Heibati, B.; Heidari, M.; Hendrie, D.; Henok, A.; Henry, N.J.; Herteliu, C.; Heydarpour, F.; Heydarpour, P.; Heydarpour, S.; Hibstu, D.T.; Hoek, H.W.; Hole, M.K.; Homaie Rad, E.; Hoogar, P.; Hosgood, H.D.; Hosseini, S.M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Hotez, P.J.; Hoy, D.G.; Hsiao, T.; Hu, G.; Huang, J.J.; Husseini, A.; Hussen, M.M.; Hutfless, S.; Idrisov, B.; Ilesanmi, O.S.; Iqbal, U.; Irvani, S.S.N.; Irvine, C.M.S.; Islam, N.; Islam, S.M.S.; Islami, F.; Jacobsen, K.H.; Jahangiry, L.; Jahanmehr, N.; Jain, S.K.; Jakovljevic, M.; Jalu, M.T.; James, S.L.; Javanbakht, M.; Jayatilleke, A.U.; Jeemon, P.; Jenkins, K.J.; Jha, R.P.; Jha, V.; Johnson, C.O.; Johnson, S.C.; Jonas, J.B.; Joshi, A.; Jozwiak, J.J.; Jungari, S.B.; Jürisson, M.; Kabir, Z.; Kadel, R.; Kahsay, A.; Kalani, R.; Karami, M.; Karami Matin, B.; Karch, A.; Karema, C.; Karimi-Sari, H.; Kasaeian, A.; Kassa, D.H.; Kassa, G.M.; Kassa, T.D.; Kassebaum, N.J.; Katikireddi, S.V.; Kaul, A.; Kazemi, Z.; Karyani, A.K.; Kazi, D.S.; Kefale, A.T.; Keiyoro, P.N.; Kemp, G.R.; Kengne, A.P.; Keren, A.; Kesavachandran, C.N.; Khader, Y.S.; Khafaei, B.; Khafaie, M.A.; Khajavi, A.; Khalid, N.; Khalil, I.A.; Khan, E.A.; Khan, M.S.; Khan, M.A.; Khang, Y-H.; Khater, M.M.; Khoja, A.T.; Khosravi, A.; Khosravi, M.H.; Khubchandani, J.; Kiadaliri, A.A.; Kibret, G.D.; Kidanemariam, Z.T.; Kiirithio, D.N.; Kim, D.; Kim, Y-E.; Kim, Y.J.; Kimokoti, R.W.; Kinfu, Y.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Knudsen, A.K.S.; Kocarnik, J.M.; Kochhar, S.; Kokubo, Y.; Kolola, T.; Kopec, J.A.; Koul, P.A.; Koyanagi, A.; Kravchenko, M.A.; Krishan, K.; Kuate Defo, B.; Kucuk Bicer, B.; Kumar, G.A.; Kumar, M.; Kumar, P.; Kutz, M.J.; Kuzin, I.; Kyu, H.H.; Lad, D.P.; Lad, S.D.; Lafranconi, A.; Lal, D.K.; Lalloo, R.; Lallukka, T.; Lam, J.O.; Lami, F.H.; Lansingh, V.C.; Lansky, S.; Larson, H.J.; Latifi, A.; Lau, K.M-M.; Lazarus, J.V.; Lebedev, G.; Lee, P.H.; Leigh, J.; Leili, M.; Leshargie, C.T.; Li, S.; Li, Y.; Liang, J.; Lim, L-L.; Lim, S.S.; Limenih, M.A.; Linn, S.; Liu, S.; Liu, Y.; Lodha, R.; Lonsdale, C.; Lopez, A.D.; Lorkowski, S.; Lotufo, P.A.; Lozano, R.; Lunevicius, R.; Ma, S.; Macarayan, E.R.K.; Mackay, M.T.; MacLachlan, J.H.; Maddison, E.R.; Madotto, F.; Magdy Abd El Razek, H.; Magdy Abd El Razek, M.; Maghavani, D.P.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Manda, A-L.; Mandarano-Filho, L.G.; Manguerra, H.; Mansournia, M.A.; Mapoma, C.C.; Marami, D.; Maravilla, J.C.; Marcenes, W.; Marczak, L.; Marks, A.; Marks, G.B.; Martinez, G.; Martins-Melo, F.R.; Martopullo, I.; März, W.; Marzan, M.B.; Masci, J.R.; Massenburg, B.B.; Mathur, M.R.; Mathur, P.; Matzopoulos, R.; Maulik, P.K.; Mazidi, M.; McAlinden, C.; McGrath, J.J.; McKee, M.; McMahon, B.J.; Mehata, S.; Mehndiratta, M.M.; Mehrotra, R.; Mehta, K.M.; Mehta, V.; Mekonnen, T.C.; Melese, A.; Melku, M.; Memiah, P.T.N.; Memish, Z.A.; Mendoza, W.; Mengistu, D.T.; Mengistu, G.; Mensah, G.A.; Mereta, S.T.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Mezgebe, H.B.; Miazgowski, B.; Miazgowski, T.; Millear, A.I.; Miller, T.R.; Miller-Petrie, M.K.; Mini, G.K.; Mirabi, P.; Mirarefin, M.; Mirica, A.; Mirrakhimov, E.M.; Misganaw, A.T.; Mitiku, H.; Moazen, B.; Mohammad, K.A.; Mohammadi, M.; Mohammadifard, N.; Mohammed, M.A.; Mohammed, S.; Mohan, V.; Mokdad, A.H.; Molokhia, M.; Monasta, L.; Moradi, G.; Moradi-Lakeh, M.; Moradinazar, M.; Moraga, P.; Morawska, L.; Moreno Velásquez, I.; Morgado-Da-Costa, J.; Morrison, S.D.; Moschos, M.M.; Mouodi, S.; Mousavi, S.M.; Muchie, K.F.; Mueller, U.O.; Mukhopadhyay, S.; Muller, K.; Mumford, J.E.; Musa, J.; Musa, K.I.; Mustafa, G.; Muthupandian, S.; Nachega, J.B.; Nagel, G.; Naheed, A.; Nahvijou, A.; Naik, G.; Nair, S.; Najafi, F.; Naldi, L.; Nam, H.S.; Nangia, V.; Nansseu, J.R.; Nascimento, B.R.; Natarajan, G.; Neamati, N.; Negoi, I.; Negoi, R.I.; Neupane, S.; Newton, C.R.J.; Ngalesoni, F.N.; Ngunjiri, J.W.; Nguyen, A.Q.; Nguyen, G.; Nguyen, H.T.; Nguyen, H.T.; Nguyen, L.H.; Nguyen, M.; Nguyen, T.H.; Nichols, E.; Ningrum, D.N.A.; Nirayo, Y.L.; Nixon, M.R.; Nolutshungu, N.; Nomura, S.; Norheim, O.F.; Noroozi, M.; Norrving, B.; Noubiap, J.J.; Nouri, H.R.; Nourollahpour Shiadeh, M.; Nowroozi, M.R.; Nyasulu, P.S.; Odell, C.M.; Ofori-Asenso, R.; Ogbo, F.A.; Oh, I-H.; Oladimeji, O.; Olagunju, A.T.; Olivares, P.R.; Olsen, H.E.; Olusanya, B.O.; Olusanya, J.O.; Ong, K.L.; Ong, S.K.S.; Oren, E.; Orpana, H.M.; Ortiz, A.; Ortiz, J.R.; Otstavnov, S.S.; Øverland, S.; Owolabi, M.O.; Özdemir, R.; P A, M.; Pacella, R.; Pakhale, S.; Pakhare, A.P.; Pakpour, A.H.; Pana, A.; Panda-Jonas, S.; Pandian, J.D.; Parisi, A.; Park, E-K.; Parry, C.D.H.; Parsian, H.; Patel, S.; Pati, S.; Patton, G.C.; Paturi, V.R.; Paulson, K.R.; Pereira, A.; Pereira, D.M.; Perico, N.; Pesudovs, K.; Petzold, M.; Phillips, M.R.; Piel, F.B.; Pigott, D.M.; Pillay, J.D.; Pirsaheb, M.; Pishgar, F.; Polinder, S.; Postma, M.J.; Pourshams, A.; Poustchi, H.; Pujar, A.; Prakash, S.; Prasad, N.; Purcell, C.A.; Qorbani, M.; Quintana, H.; Quistberg, D.A.; Rade, K.W.; Radfar, A.; Rafay, A.; Rafiei, A.; Rahim, F.; Rahimi, K.; Rahimi-Movaghar, A.; Rahman, M.; Rahman, M.H.U.; Rahman, M.A.; Rai, R.K.; Rajsic, S.; Ram, U.; Ranabhat, C.L.; Ranjan, P.; Rao, P.C.; Rawaf, D.L.; Rawaf, S.; Razo-García, C.; Reddy, K.S.; Reiner, R.C.; Reitsma, M.B.; Remuzzi, G.; Renzaho, A.M.N.; Resnikoff, S.; Rezaei, S.; Rezaeian, S.; Rezai, M.S.; Riahi, S.M.; Ribeiro, A.L.P.; Rios-Blancas, M.J.; Roba, K.T.; Roberts, N.L.S.; Robinson, S.R.; Roever, L.; Ronfani, L.; Roshandel, G.; Rostami, A.; Rothenbacher, D.; Roy, A.; Rubagotti, E.; Sachdev, P.S.; Saddik, B.; Sadeghi, E.; Safari, H.; Safdarian, M.; Safi, S.; Safiri, S.; Sagar, R.; Sahebkar, A.; Sahraian, M.A.; Salam, N.; Salama, J.S.; Salamati, P.; Saldanha, R.D.F.; Saleem, Z.; Salimi, Y.; Salvi, S.S.; Salz, I.; Sambala, E.Z.; Samy, A.M.; Sanabria, J.; Sanchez-Niño, M.D.; Santomauro, D.F.; Santos, I.S.; Santos, J.V.; Milicevic, M.M.S.; Sao Jose, B.P.; Sarker, A.R.; Sarmiento-Suárez, R.; Sarrafzadegan, N.; Sartorius, B.; Sarvi, S.; Sathian, B.; Satpathy, M.; Sawant, A.R.; Sawhney, M.; Saxena, S.; Sayyah, M.; Schaeffner, E.; Schmidt, M.I.; Schneider, I.J.C.; Schöttker, B.; Schutte, A.E.; Schwebel, D.C.; Schwendicke, F.; Scott, J.G.; Sekerija, M.; Sepanlou, S.G.; Serván-Mori, E.; Seyedmousavi, S.; Shabaninejad, H.; Shackelford, K.A.; Shafieesabet, A.; Shahbazi, M.; Shaheen, A.A.; Shaikh, M.A.; Shams-Beyranvand, M.; Shamsi, M.; Shamsizadeh, M.; Sharafi, K.; Sharif, M.; Sharif-Alhoseini, M.; Sharma, R.; She, J.; Sheikh, A.; Shi, P.; Shiferaw, M.S.; Shigematsu, M.; Shiri, R.; Shirkoohi, R.; Shiue, I.; Shokraneh, F.; Shrime, M.G.; Si, S.; Siabani, S.; Siddiqi, T.J.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silberberg, D.H.; Silva, D.A.S.; Silva, J.P.; Silva, N.T.D.; Silveira, D.G.A.; Singh, J.A.; Singh, N.P.; Singh, P.K.; Singh, V.; Sinha, D.N.; Sliwa, K.; Smith, M.; Sobaih, B.H.; Sobhani, S.; Sobngwi, E.; Soneji, S.S.; Soofi, M.; Sorensen, R.J.D.; Soriano, J.B.; Soyiri, I.N.; Sposato, L.A.; Sreeramareddy, C.T.; Srinivasan, V.; Stanaway, J.D.; Starodubov, V.I.; Stathopoulou, V.; Stein, D.J.; Steiner, C.; Stewart, L.G.; Stokes, M.A.; Subart, M.L.; Sudaryanto, A.; Sufiyan, M.B.; Sur, P.J.; Sutradhar, I.; Sykes, B.L.; Sylaja, P.N.; Sylte, D.O.; Szoeke, C.E.I.; Tabarés-Seisdedos, R.; Tabuchi, T.; Tadakamadla, S.K.; Takahashi, K.; Tandon, N.; Tassew, S.G.; Taveira, N.; Tehrani-Banihashemi, A.; Tekalign, T.G.; Tekle, M.G.; Temsah, M-H.; Temsah, O.; Terkawi, A.S.; Teshale, M.Y.; Tessema, B.; Tessema, G.A.; Thankappan, K.R.; Thirunavukkarasu, S.; Thomas, N.; Thrift, A.G.; Thurston, G.D.; Tilahun, B.; To, Q.G.; Tobe-Gai, R.; Tonelli, M.; Topor-Madry, R.; Torre, A.E.; Tortajada-Girbés, M.; Touvier, M.; Tovani-Palone, M.R.; Tran, B.X.; Tran, K.B.; Tripathi, S.; Troeger, C.E.; Truelsen, T.C.; Truong, N.T.; Tsadik, A.G.; Tsoi, D.; Tudor Car, L.; Tuzcu, E.M.; Tyrovolas, S.; Ukwaja, K.N.; Ullah, I.; Undurraga, E.A.; Updike, R.L.; Usman, M.S.; Uthman, O.A.; Uzun, S.B.; Vaduganathan, M.; Vaezi, A.; Vaidya, G.; Valdez, P.R.; Varavikova, E.; Vasankari, T.J.; Venketasubramanian, N.; Villafaina, S.; Violante, F.S.; Vladimirov, S.K.; Vlassov, V.; Vollset, S.E.; Vos, T.; Wagner, G.R.; Wagnew, F.S.; Waheed, Y.; Wallin, M.T.; Walson, J.L.; Wang, Y.; Wang, Y-P.; Wassie, M.M.; Weiderpass, E.; Weintraub, R.G.; Weldegebreal, F.; Weldegwergs, K.G.; Werdecker, A.; Werkneh, A.A.; West, T.E.; Westerman, R.; Whiteford, H.A.; Widecka, J.; Wilner, L.B.; Wilson, S.; Winkler, A.S.; Wiysonge, C.S.; Wolfe, C.D.A.; Wu, S.; Wu, Y-C.; Wyper, G.M.A.; Xavier, D.; Xu, G.; Yadgir, S.; Yadollahpour, A.; Yahyazadeh Jabbari, S.H.; Yakob, B.; Yan, L.L.; Yano, Y.; Yaseri, M.; Yasin, Y.J.; Yentür, G.K.; Yeshaneh, A.; Yimer, E.M.; Yip, P.; Yirsaw, B.D.; Yisma, E.; Yonemoto, N.; Yonga, G.; Yoon, S-J.; Yotebieng, M.; Younis, M.Z.; Yousefifard, M.; Yu, C.; Zadnik, V.; Zaidi, Z.; Zaman, S.B.; Zamani, M.; Zare, Z.; Zeleke, A.J.; Zenebe, Z.M.; Zhang, A.L.; Zhang, K.; Zhou, M.; Zodpey, S.; Zuhlke, L.J.; Naghavi, M.; Murray, C.J.L. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159), 1736-1788.
[http://dx.doi.org/10.1016/S0140-6736(18)32203-7] [PMID: 30496103]
[41]
Damaskos, C.; Garmpis, N.; Kollia, P.; Mitsiopoulos, G.; Barlampa, D.; Drosos, A.; Patsouras, A.; Gravvanis, N.; Antoniou, V.; Litos, A.; Diamantis, E. Assessing cardiovascular risk in patients with diabetes: An update. Curr. Cardiol. Rev., 2021, 16(4), 266-274.
[http://dx.doi.org/10.2174/1573403X15666191111123622] [PMID: 31713488]
[42]
Toborek, M.; Barger, S.W.; Mattson, M.P.; Barve, S.; McClain, C.J.; Hennig, B. Linoleic acid and TNF-alpha cross-amplify oxidative injury and dysfunction of endothelial cells. J. Lipid Res., 1996, 37(1), 123-135.
[http://dx.doi.org/10.1016/S0022-2275(20)37641-0] [PMID: 8820108]
[43]
Peng, M.; Fu, Y.; Wu, C.; Zhang, Y.; Ren, H.; Zhou, S. Signaling pathways related to oxidative stress in diabetic cardiomyopathy. Front. Endocrinol., 2022, 13, 907757.
[http://dx.doi.org/10.3389/fendo.2022.907757] [PMID: 35784531]
[44]
Seferović, P.M.; Petrie, M.C.; Filippatos, G.S.; Anker, S.D.; Rosano, G.; Bauersachs, J.; Paulus, W.J.; Komajda, M.; Cosentino, F.; de Boer, R.A.; Farmakis, D.; Doehner, W.; Lambrinou, E.; Lopatin, Y.; Piepoli, M.F.; Theodorakis, M.J.; Wiggers, H.; Lekakis, J.; Mebazaa, A.; Mamas, M.A.; Tschöpe, C.; Hoes, A.W.; Seferović, J.P.; Logue, J.; McDonagh, T.; Riley, J.P.; Milinković, I.; Polovina, M.; van Veldhuisen, D.J.; Lainscak, M.; Maggioni, A.P.; Ruschitzka, F.; McMurray, J.J.V. Type 2 diabetes mellitus and heart failure: A position statement from the heart failure association of the european society of cardiology. Eur. J. Heart Fail., 2018, 20(5), 853-872.
[http://dx.doi.org/10.1002/ejhf.1170] [PMID: 29520964]
[45]
Forbes, J.M.; Cooper, M.E. Mechanisms of diabetic complications. Physiol. Rev., 2013, 93(1), 137-188.
[http://dx.doi.org/10.1152/physrev.00045.2011] [PMID: 23303908]
[46]
Makrilakis, K.; Liatis, S. Cardiovascular screening for the asymptomatic patient with diabetes: More cons than pros. J. Diabetes Res., 2017, 2017, 1-19.
[http://dx.doi.org/10.1155/2017/8927473] [PMID: 29387731]
[47]
Tanaskovic, S.; Isenovic, E.R.; Radak, D. Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy--evidence from clinical studies. Angiology, 2011, 62(7), 535-542.
[http://dx.doi.org/10.1177/0003319710398010] [PMID: 21873348]
[48]
Radak, D.; Katsiki, N.; Resanovic, I.; Jovanovic, A.; Sudar-Milovanovic, E.; Zafirovic, S.; Mousad, S.A.; Isenovic, E.R. Apoptosis and acute brain ischemia in ischemic stroke. Curr. Vasc. Pharmacol., 2017, 15(2), 115-122.
[http://dx.doi.org/10.2174/1570161115666161104095522] [PMID: 27823556]
[49]
Nativel, M.; Potier, L.; Alexandre, L.; Baillet-Blanco, L.; Ducasse, E.; Velho, G.; Marre, M.; Roussel, R.; Rigalleau, V.; Mohammedi, K. Lower extremity arterial disease in patients with diabetes: A contemporary narrative review. Cardiovasc Diabetol., 2018, 17(1), 138.
[http://dx.doi.org/10.1186/s12933-018-0781-1]
[50]
Resanović, I.; Gluvić, Z.; Zarić, B.; Sudar-Milovanović, E.; Vučić, V.; Arsić, A.; Nedić, O.; Šunderić, M.; Gligorijević, N.; Milačić, D.; Isenović, E.R. Effect of hyperbaric oxygen therapy on fatty acid composition and insulin-like growth factor binding protein 1 in adult type 1 diabetes mellitus patients: A pilot study. Can. J. Diabetes, 2020, 44(1), 22-29.
[http://dx.doi.org/10.1016/j.jcjd.2019.04.018] [PMID: 31311728]
[51]
Xu, G-T.; Zhang, J-F.; Tang, L. Inflammation in diabetic retinopathy: Possible roles in pathogenesis and potential implications for therapy. Neural Regen. Res., 2023, 18(5), 976-982.
[http://dx.doi.org/10.4103/1673-5374.355743] [PMID: 36254977]
[52]
Chudasama, Y.V.; Khunti, K. Healthy lifestyle choices and microvascular complications: New insights into diabetes management. PLoS Med., 2023, 20(1), e1004152.
[53]
Sanaye, M.M.; Kavishwar, S.A. Diabetic neuropathy: Review on molecular mechanisms. Curr. Mol. Med., 2023, 23(2), 97-110.
[http://dx.doi.org/10.2174/1566524021666210816093111] [PMID: 34397329]
[54]
Wang, P.; Guo, R.; Bai, X.; Cui, W.; Zhang, Y.; Li, H.; Shang, J.; Zhao, Z. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice. Front. Endocrinol., 2022, 13, 1034818.
[http://dx.doi.org/10.3389/fendo.2022.1034818] [PMID: 36589853]
[55]
McGuire, D.K.; Shih, W.J.; Cosentino, F.; Charbonnel, B.; Cherney, D.Z.I.; Dagogo-Jack, S.; Pratley, R.; Greenberg, M.; Wang, S.; Huyck, S.; Gantz, I.; Terra, S.G.; Masiukiewicz, U.; Cannon, C.P. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol., 2021, 6(2), 148-158.
[http://dx.doi.org/10.1001/jamacardio.2020.4511] [PMID: 33031522]
[56]
Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 2019, 380(24), 2295-2306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[57]
Baigent, C.; Emberson, J.R.; Haynes, R.; Herrington, W.G.; Judge, P.; Landray, M.J.; Mayne, K.J.; Ng, S.Y.A.; Preiss, D.; Roddick, A.J.; Staplin, N.; Zhu, D.; Anker, S.D.; Bhatt, D.L.; Brueckmann, M.; Butler, J.; Cherney, D.Z.I.; Green, J.B.; Hauske, S.J.; Haynes, R.; Heerspink, H.J.L.; Herrington, W.G.; Inzucchi, S.E.; Jardine, M.J.; Liu, C-C.; Mahaffey, K.W.; McCausland, F.R.; McGuire, D.K.; McMurray, J.J.V.; Neal, B.; Neuen, B.L.; Packer, M.; Perkovic, V.; Sabatine, M.S.; Solomon, S.D.; Vaduganathan, M.; Wanner, C.; Wheeler, D.C.; Wiviott, S.D.; Zannad, F. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 2022, 400(10365), 1788-1801.
[http://dx.doi.org/10.1016/S0140-6736(22)02074-8] [PMID: 36351458]
[58]
Bonora, B.M.; Avogaro, A.; Fadini, G.P. Extraglycemic effects of SGLT2 inhibitors: A review of the evidence. Diabetes Metab. Syndr. Obes., 2020, 13, 161-174.
[http://dx.doi.org/10.2147/DMSO.S233538] [PMID: 32021362]
[59]
Ishibashi, F.; Kosaka, A.; Tavakoli, M. Sodium glucose cotransporter-2 inhibitor protects against diabetic neuropathy and nephropathy in modestly controlled type 2 diabetes: Follow-up study. Front. Endocrinol., 2022, 13(864332), 864332.
[http://dx.doi.org/10.3389/fendo.2022.864332] [PMID: 35784562]
[60]
Anders, H.J.; Davis, J.M.; Thurau, K. Nephron protection in diabetic kidney disease. N. Engl. J. Med., 2016, 375(21), 2096-2098.
[http://dx.doi.org/10.1056/NEJMcibr1608564] [PMID: 27959742]
[61]
Cherney, D.Z.I.; Perkins, B.A.; Soleymanlou, N.; Har, R.; Fagan, N.; Johansen, O.; Woerle, H.J.; von Eynatten, M.; Broedl, U.C. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol., 2014, 13(1), 28.
[http://dx.doi.org/10.1186/1475-2840-13-28] [PMID: 24475922]
[62]
Podestà, M.A.; Sabiu, G.; Galassi, A.; Ciceri, P.; Cozzolino, M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines, 2023, 11(2), 279.
[http://dx.doi.org/10.3390/biomedicines11020279] [PMID: 36830815]
[63]
Nedosugova, L.V.; Markina, Y.V. Inflammatory mechanisms of diabetes and its vascular complications. Biomedicines, 2022, 10(5), 1168.
[http://dx.doi.org/10.3390/biomedicines10051168]
[64]
ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Das, S.R.; Hilliard, M.E.; Isaacs, D.; Johnson, E.L.; Kahan, S.; Khunti, K.; Kosiborod, M.; Leon, J.; Lyons, S.K.; Perry, M.L.; Prahalad, P.; Pratley, R.E.; Seley, J.J.; Stanton, R.C.; Gabbay, R.A. Cardiovascular disease and risk management: Standards of care in diabetes-2023. Diabetes Care, 2023, 46(Suppl. 1), S158-S190.
[http://dx.doi.org/10.2337/dc23-S010] [PMID: 36507632]
[65]
Isenovic, E.R. Clinical approach for the treatment of obesity-associated diseases. Curr. Pharm. Des., 2019, 25(18), 2017-2018.
[http://dx.doi.org/10.2174/138161282518190822153931] [PMID: 31538880]
[66]
Zaric, B.L.; Obradovic, M.; Sudar-Milovanovic, E.; Nedeljkovic, J.; Lazic, V.; Isenovic, E.R. Drug delivery systems for diabetes treatment. Curr. Pharm. Des., 2019, 25(2), 166-173.
[http://dx.doi.org/10.2174/1381612825666190306153838] [PMID: 30848184]
[67]
Isenovic, E.; Meng, Y.; Jamali, N.; Milivojevic, N.; Sowers, J. Ang II attenuates IGF-1-stimulated Na+, K+-ATPase activity via PI3K/Akt pathway in vascular smooth muscle cells. Int. J. Mol. Med., 2004, 13(6), 915-922.
[http://dx.doi.org/10.3892/ijmm.13.6.915] [PMID: 15138635]
[68]
Isenovic, E.R.; Jacobs, D.B.; Kedees, M.H.; Sha, Q.; Milivojevic, N.; Kawakami, K.; Gick, G.; Sowers, J.R. Angiotensin II regulation of the Na+ pump involves the phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways in vascular smooth muscle cells. Endocrinology, 2004, 145(3), 1151-1160.
[http://dx.doi.org/10.1210/en.2003-0100] [PMID: 14630723]
[69]
Wright, E.M.; Turk, E. The sodium/glucose cotransport family SLC5. Pflugers Arch., 2004, 447(5), 813-815.
[http://dx.doi.org/10.1007/s00424-003-1202-0] [PMID: 12748858]
[70]
Boyd, C.A.R. Facts, fantasies and fun in epithelial physiology. Exp. Physiol., 2008, 93(3), 303-314.
[http://dx.doi.org/10.1113/expphysiol.2007.037523] [PMID: 18192340]
[71]
Kanai, Y.; Lee, W.S.; You, G.; Brown, D.; Hediger, M.A. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Invest., 1994, 93(1), 397-404.
[http://dx.doi.org/10.1172/JCI116972] [PMID: 8282810]
[72]
Zhao, F.Q.; Keating, A. Functional properties and genomics of glucose transporters. Curr. Genomics, 2007, 8(2), 113-128.
[http://dx.doi.org/10.2174/138920207780368187] [PMID: 18660845]
[73]
Sabolić, I.; Vrhovac, I.; Eror, D.B.; Gerasimova, M.; Rose, M.; Breljak, D.; Ljubojević, M.; Brzica, H.; Sebastiani, A.; Thal, S.C.; Sauvant, C.; Kipp, H.; Vallon, V.; Koepsell, H. Expression of Na +-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am. J. Physiol. Cell Physiol., 2012, 302(8), C1174-C1188.
[http://dx.doi.org/10.1152/ajpcell.00450.2011] [PMID: 22262063]
[74]
Balen, D.; Ljubojević, M.; Breljak, D.; Brzica, H.; Z̆lender, V.; Koepsell, H.; Sabolić, I. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am. J. Physiol. Cell Physiol., 2008, 295(2), C475-C489.
[http://dx.doi.org/10.1152/ajpcell.00180.2008] [PMID: 18524944]
[75]
Bonner, C.; Kerr-Conte, J.; Gmyr, V.; Queniat, G.; Moerman, E.; Thévenet, J.; Beaucamps, C.; Delalleau, N.; Popescu, I.; Malaisse, W.J.; Sener, A.; Deprez, B.; Abderrahmani, A.; Staels, B.; Pattou, F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med., 2015, 21(5), 512-517.
[http://dx.doi.org/10.1038/nm.3828] [PMID: 25894829]
[76]
Ehrenkranz, J.R.L.; Lewis, N.G.; Ronald Kahn, C.; Roth, J. Phlorizin: A review. Diabetes Metab. Res. Rev., 2005, 21(1), 31-38.
[http://dx.doi.org/10.1002/dmrr.532] [PMID: 15624123]
[77]
Ramani, J.; Shah, H.; Vyas, V.K.; Sharma, M. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European J. Med. Chem. Reports, 2022, 6, 100074.
[http://dx.doi.org/10.1016/j.ejmcr.2022.100074]
[78]
Dardi, I.; Kouvatsos, T.; Jabbour, S.A. SGLT2 inhibitors. Biochem. Pharmacol., 2016, 101, 27-39.
[http://dx.doi.org/10.1016/j.bcp.2015.09.005] [PMID: 26362302]
[79]
Rieg, T.; Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia, 2018, 61(10), 2079-2086.
[http://dx.doi.org/10.1007/s00125-018-4654-7] [PMID: 30132033]
[80]
Link, J.T.; Sorensen, B.K. A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett., 2000, 41(48), 9213-9217.
[http://dx.doi.org/10.1016/S0040-4039(00)01709-3]
[81]
Meng, W.; Ellsworth, B.A.; Nirschl, A.A.; McCann, P.J.; Patel, M.; Girotra, R.N.; Wu, G.; Sher, P.M.; Morrison, E.P.; Biller, S.A.; Zahler, R.; Deshpande, P.P.; Pullockaran, A.; Hagan, D.L.; Morgan, N.; Taylor, J.R.; Obermeier, M.T.; Humphreys, W.G.; Khanna, A.; Discenza, L.; Robertson, J.G.; Wang, A.; Han, S.; Wetterau, J.R.; Janovitz, E.B.; Flint, O.P.; Whaley, J.M.; Washburn, W.N. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2008, 51(5), 1145-1149.
[http://dx.doi.org/10.1021/jm701272q] [PMID: 18260618]
[82]
Manoj, A.; Das, S. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review. Future Med. Chem., 2020, 12(21), 1961-1990.
[83]
Cai, W.; Jiang, L.; Xie, Y.; Liu, Y.; Liu, W.; Zhao, G. Design of SGLT2 inhibitors for the treatment of type 2 diabetes: A history driven by biology to chemistry. Med. Chem., 2015, 11(4), 317-328.
[http://dx.doi.org/10.2174/1573406411666150105105529] [PMID: 25557661]
[84]
Marrs, J.C.; Anderson, S.L. Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context, 2020, 9, 1-10.
[http://dx.doi.org/10.7573/dic.2020-7-4] [PMID: 33293984]
[85]
Azzam, O.; Carnagarin, R.; Lugo-Gavidia, L.M.; Nolde, J.; Matthews, V.B.; Schlaich, M.P. Bexagliflozin for type 2 diabetes: An overview of the data. Expert Opin. Pharmacother., 2021, 22(16), 2095-2103.
[http://dx.doi.org/10.1080/14656566.2021.1959915]
[86]
Allegretti, A.S.; Zhang, W.; Zhou, W.; Thurber, T.K.; Rigby, S.P.; Bowman-Stroud, C.; Trescoli, C.; Serusclat, P.; Freeman, M.W.; Halvorsen, Y.D.C. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am. J. Kidney Dis., 2019, 74(3), 328-337.
[http://dx.doi.org/10.1053/j.ajkd.2019.03.417] [PMID: 31101403]
[87]
Kasichayanula, S.; Liu, X.; LaCreta, F.; Griffen, S.C.; Boulton, D.W. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin. Pharmacokinet., 2014, 53(1), 17-27.
[http://dx.doi.org/10.1007/s40262-013-0104-3] [PMID: 24105299]
[88]
Devineni, D.; Curtin, C.R.; Polidori, D.; Gutierrez, M.J.; Murphy, J.; Rusch, S.; Rothenberg, P.L. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol., 2013, 53(6), 601-610.
[http://dx.doi.org/10.1002/jcph.88] [PMID: 23670707]
[89]
Heise, T.; Seewaldt-Becker, E.; Macha, S.; Hantel, S.; Pinnetti, S.; Seman, L.; Woerle, H.J. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab., 2013, 15(7), 613-621.
[http://dx.doi.org/10.1111/dom.12073] [PMID: 23356556]
[90]
Fediuk, D.J.; Nucci, G.; Dawra, V.K.; Cutler, D.L.; Amin, N.B.; Terra, S.G.; Boyd, R.A.; Krishna, R.; Sahasrabudhe, V. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) Inhibitor. Clin. Pharmacokinet., 2020, 59(8), 949-965.
[http://dx.doi.org/10.1007/s40262-020-00875-1] [PMID: 32337660]
[91]
Ohno, H.; Kojima, Y.; Harada, H.; Abe, Y.; Endo, T.; Kobayashi, M. Absorption, disposition, metabolism and excretion of [ 14 C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica, 2019, 49(4), 463-473.
[http://dx.doi.org/10.1080/00498254.2018.1449269] [PMID: 29558223]
[92]
Inoue, T.; Takemura, M.; Fushimi, N.; Fujimori, Y.; Onozato, T.; Kurooka, T.; Asari, T.; Takeda, H.; Kobayashi, M.; Nishibe, H.; Isaji, M. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur. J. Pharmacol., 2017, 806, 25-31.
[http://dx.doi.org/10.1016/j.ejphar.2017.04.010] [PMID: 28410751]
[93]
Fukudo, S.; Endo, Y.; Hongo, M.; Nakajima, A.; Abe, T.; Kobayashi, H.; Nakata, T.; Nakajima, T.; Sameshima, K.; Kaku, K.; Shoji, E.; Tarumi, K.; Nagaoka, Y.; Ooshima, T.; Ozawa, K.; Majima, T.; Kamata, S.; Tada, T.; Ishii, H.; Segawa, Y.; Miyazaki, S.; Yamamoto, T.; Yagi, Y.; Sawada, H.; Shirota, S.; Otsuka, S.; Yamada, N.; Suzuki, R.; Kurakata, H.; Nakai, K.; Syuji, Y.; Usui, T.; Yamamura, M.; Oishi, T.; Tanaka, H. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: A randomised, placebo-controlled, double-blind phase 2 trial. Lancet Gastroenterol. Hepatol., 2018, 3(9), 603-613.
[http://dx.doi.org/10.1016/S2468-1253(18)30165-1] [PMID: 30056028]
[94]
Markham, A.; Keam, S.J. Sotagliflozin: First global approval. Drugs, 2019, 79(9), 1023-1029.
[http://dx.doi.org/10.1007/s40265-019-01146-5] [PMID: 31172412]
[95]
Buse, J.B.; Garg, S.K.; Rosenstock, J.; Bailey, T.S.; Banks, P.; Bode, B.W.; Danne, T.; Kushner, J.A.; Lane, W.S.; Lapuerta, P.; McGuire, D.K.; Peters, A.L.; Reed, J.; Sawhney, S.; Strumph, P. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The north American intandem1 study. Diabetes Care, 2018, 41(9), 1970-1980.
[http://dx.doi.org/10.2337/dc18-0343] [PMID: 29937430]
[96]
Danne, T.; Cariou, B.; Banks, P.; Brandle, M.; Brath, H.; Franek, E.; Kushner, J.A.; Lapuerta, P.; McGuire, D.K.; Peters, A.L.; Sawhney, S.; Strumph, P. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: The european intandem2 study. Diabetes Care, 2018, 41(9), 1981-1990.
[http://dx.doi.org/10.2337/dc18-0342] [PMID: 29937431]
[97]
Zambrowicz, B.; Freiman, J.; Brown, P.M.; Frazier, K.S.; Turnage, A.; Bronner, J.; Ruff, D.; Shadoan, M.; Banks, P.; Mseeh, F.; Rawlins, D.B.; Goodwin, N.C.; Mabon, R.; Harrison, B.A.; Wilson, A.; Sands, A.; Powell, D.R. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin. Pharmacol. Ther., 2012, 92(2), 158-169.
[http://dx.doi.org/10.1038/clpt.2012.58] [PMID: 22739142]
[98]
Rosenstock, J.; Cefalu, W.T.; Lapuerta, P.; Zambrowicz, B.; Ogbaa, I.; Banks, P.; Sands, A. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care, 2015, 38(3), 431-438.
[http://dx.doi.org/10.2337/dc14-0890] [PMID: 25216510]
[99]
Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; Bhatt, D.L. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl. J. Med., 2019, 380(4), 347-357.
[100]
Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med., 2017, 377(7), 644-657.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[101]
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117-2128.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[102]
Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R.A. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study. Diabetes Care, 2016, 39(5), 717-725.
[http://dx.doi.org/10.2337/dc16-0041] [PMID: 27208375]
[103]
Fitchett, D.; Inzucchi, S.E.; Lachin, J.M.; Wanner, C.; van de Borne, P.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; George, J.T.; Zinman, B. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J. Am. Coll. Cardiol., 2018, 71(3), 364-367.
[http://dx.doi.org/10.1016/j.jacc.2017.11.022] [PMID: 29348030]
[104]
Grunberger, G.; Camp, S.; Johnson, J.; Huyck, S.; Terra, S.G.; Mancuso, J.P.; Jiang, Z.W.; Golm, G.; Engel, S.S.; Lauring, B. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study. Diabetes Ther., 2018, 9(1), 49-66.
[http://dx.doi.org/10.1007/s13300-017-0337-5] [PMID: 29159457]
[105]
Aronson, R.; Frias, J. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes. Metab., 2018, 20(6), 1453-1460.
[106]
Hopf, M.; Kloos, C.; Wolf, G.; Müller, U.A. Effectiveness and safety of SGLT2 inhibitors in clinical routine treatment of patients with diabetes mellitus type 2. J. Clin. Med., 2021, 10(4), 571.
[107]
McGovern, A.P.; Hogg, M.; Shields, B.M.; Sattar, N.A.; Holman, R.R.; Pearson, E.R.; Hattersley, A.T.; Jones, A.G.; Dennis, J.M. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res. Care, 2020, 8(1), e001238.
[http://dx.doi.org/10.1136/bmjdrc-2020-001238] [PMID: 32448787]
[108]
Arnott, C.; Huang, Y.; Neuen, B.L. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes. Metab., 2020, 22(10), 1735-1766.
[http://dx.doi.org/10.1111/dom.14091]
[109]
Furtado, R.H.M.; Raz, I.; Goodrich, E.L.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Aylward, P.; Dalby, A.J.; Dellborg, M.; Dimulescu, D.; Nicolau, J.C.; Oude Ophuis, A.J.M.; Cahn, A.; Mosenzon, O.; Gause-Nilsson, I.; Langkilde, A.M.; Sabatine, M.S.; Wiviott, S.D. Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: Observations from DECLARE-TIMI 58 Trial. Circulation, 2022, 145(21), 1581-1591.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.058103] [PMID: 35510542]
[110]
Toyama, T.; Neuen, B.L. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes. Metab., 2019, 21(5), 1237-1250.
[http://dx.doi.org/10.1111/dom.13648]
[111]
Fukuda, M.; Nabeta, M.; Muta, T.; Fukami, K.; Takasu, O. Euglycemic diabetic ketoacidosis caused by canagliflozin: A case report. Int. J. Emerg. Med., 2020, 13(1), 020-0261.
[http://dx.doi.org/10.1186/s12245-020-0261-8]
[112]
Luo, X.; Ji, R.; Lu, W.; Zhu, H.; Li, L.; Hu, J. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient who underwent surgery for pancreatic carcinoma: A case report. Front. Surg., 2022, 9, 769041.
[http://dx.doi.org/10.3389/fsurg.2022.769041]
[113]
Altowayan, W.M. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann. Med. Surg., 2022, 84, 104879.
[http://dx.doi.org/10.1016/j.amsu.2022.104879]
[114]
Chandrakumar, H.P.; Chillumuntala, S.; Singh, G.; McFarlane, S.I. Postoperative euglycemic ketoacidosis in type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitor: Insights into pathogenesis and management strategy. Cureus, 2021, 13(6), e15533.
[http://dx.doi.org/10.7759/cureus.15533] [PMID: 34123681]
[115]
Donnan, J.R.; Grandy, C.A.; Chibrikov, E.; Marra, C.A.; Aubrey-Bassler, K.; Johnston, K.; Swab, M.; Hache, J.; Curnew, D.; Nguyen, H.; Gamble, J.M. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open, 2019, 9(1), e022577.
[116]
Danne, T.; Garg, S.; Peters, A.L.; Buse, J.B.; Mathieu, C.; Pettus, J.H.; Alexander, C.M.; Battelino, T.; Ampudia-Blasco, F.J.; Bode, B.W.; Cariou, B.; Close, K.L.; Dandona, P.; Dutta, S.; Ferrannini, E.; Fourlanos, S.; Grunberger, G.; Heller, S.R.; Henry, R.R.; Kurian, M.J.; Kushner, J.A.; Oron, T.; Parkin, C.G.; Pieber, T.R.; Rodbard, H.W.; Schatz, D.; Skyler, J.S.; Tamborlane, W.V.; Yokote, K.; Phillip, M. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42(6), 1147-1154.
[http://dx.doi.org/10.2337/dc18-2316] [PMID: 30728224]
[117]
Zhou, Z.; Jardine, M.; Perkovic, V.; Matthews, D.R.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Desai, M.; Oh, R.; Simpson, R.; Watts, N.B.; Neal, B. Canagliflozin and fracture risk in individuals with type 2 diabetes: Results from the CANVAS Program. Diabetologia, 2019, 62(10), 1854-1867.
[http://dx.doi.org/10.1007/s00125-019-4955-5] [PMID: 31399845]
[118]
Blau, J.E.; Taylor, S.I. Adverse effects of SGLT2 inhibitors on bone health. Nat. Rev. Nephrol., 2018, 14(8), 473-474.
[http://dx.doi.org/10.1038/s41581-018-0028-0] [PMID: 29875481]
[119]
Saisho, Y. SGLT2 inhibitors: The star in the treatment of type 2 diabetes? Diseases, 2020, 8(2), 14.
[http://dx.doi.org/10.3390/diseases8020014] [PMID: 32403420]
[120]
Taylor, S.I.; Yazdi, Z.S.; Beitelshees, A.L. Pharmacological treatment of hyperglycemia in type 2 diabetes. J. Clin. Invest., 2021, 131(2), e142243.
[http://dx.doi.org/10.1172/JCI142243] [PMID: 33463546]
[121]
Khoo, C.M.; Deerochanawong, C. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. Diabetes Obes. Metab., 2021, 23(2), 299-317.
[122]
Bloomgarden, Z.; Handelsman, Y. Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am. J. Preventive Cardiol., 2020, 1, 100007.
[123]
Xu, B.; Li, S.; Kang, B.; Zhou, J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc. Diabetol., 2022, 21(1), 83.
[http://dx.doi.org/10.1186/s12933-022-01512-w]
[124]
Dhillon, S. Dapagliflozin: A review in type 2 diabetes. Drugs, 2019, 79(10), 1135-1146.
[http://dx.doi.org/10.1007/s40265-019-01148-3] [PMID: 31236801]
[125]
Elkinson, S.; Scott, L.J. Canagliflozin: First global approval. Drugs, 2013, 73(9), 979-988.
[http://dx.doi.org/10.1007/s40265-013-0064-9] [PMID: 23729000]
[126]
Markham, A. Ertugliflozin: First global approval. Drugs, 2018, 78(4), 513-519.
[http://dx.doi.org/10.1007/s40265-018-0878-6] [PMID: 29476348]
[127]
Scott, L.J. Empagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs, 2014, 74(15), 1769-1784.
[http://dx.doi.org/10.1007/s40265-014-0298-1] [PMID: 25274537]
[128]
Plosker, G.L. Dapagliflozin: A review of its use in patients with type 2 diabetes. Drugs, 2014, 74(18), 2191-2209.
[http://dx.doi.org/10.1007/s40265-014-0324-3] [PMID: 25389049]
[129]
Fonseca-Correa, J.I.; Correa-Rotter, R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. Front. Med., 2021, 8, 777861.
[http://dx.doi.org/10.3389/fmed.2021.777861] [PMID: 34988095]
[130]
Chiba, Y.; Yamada, T.; Tsukita, S.; Takahashi, K.; Munakata, Y.; Shirai, Y.; Kodama, S.; Asai, Y.; Sugisawa, T.; Uno, K.; Sawada, S.; Imai, J.; Nakamura, K.; Katagiri, H. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLoS One, 2016, 11(3), e0150756.
[http://dx.doi.org/10.1371/journal.pone.0150756] [PMID: 26963613]
[131]
Yoshikawa, T.; Kishi, T.; Shinohara, K.; Takesue, K.; Shibata, R.; Sonoda, N.; Inoguchi, T.; Sunagawa, K.; Tsutsui, H.; Hirooka, Y. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res., 2017, 40(7), 646-651.
[132]
Matthews, V.B.; Elliot, R.H.; Rudnicka, C.; Hricova, J.; Herat, L.; Schlaich, M.P. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J. Hypertens., 2017, 35(10), 2059-2068.
[http://dx.doi.org/10.1097/HJH.0000000000001434] [PMID: 28598954]
[133]
Kimmerly, D.S.; Shoemaker, J.K. Hypovolemia and neurovascular control during orthostatic stress. Am. J. Physiol. Heart Circ. Physiol., 2002, 282(2), H645-H655.
[http://dx.doi.org/10.1152/ajpheart.00535.2001] [PMID: 11788414]
[134]
Jordan, J.; Tank, J.; Heusser, K.; Heise, T.; Wanner, C.; Heer, M.; Macha, S.; Mattheus, M.; Lund, S.S.; Woerle, H.J.; Broedl, U.C. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J. Am. Soc. Hypertens., 2017, 11(9), 604-612.
[http://dx.doi.org/10.1016/j.jash.2017.07.005] [PMID: 28757109]
[135]
Sano, M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J. Cardiol., 2018, 71(5), 471-476.
[http://dx.doi.org/10.1016/j.jjcc.2017.12.004] [PMID: 29415819]
[136]
Garvey, W.T.; Van Gaal, L.; Leiter, L.A.; Vijapurkar, U.; List, J.; Cuddihy, R.; Ren, J.; Davies, M.J. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism, 2018, 85, 32-37.
[http://dx.doi.org/10.1016/j.metabol.2018.02.002] [PMID: 29452178]
[137]
Mudaliar, S.; Henry, R.R.; Boden, G.; Smith, S.; Chalamandaris, A.G.; Duchesne, D.; Iqbal, N.; List, J. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol. Ther., 2014, 16(3), 137-144.
[http://dx.doi.org/10.1089/dia.2013.0167] [PMID: 24237386]
[138]
Hayashi, T.; Fukui, T.; Nakanishi, N.; Yamamoto, S.; Tomoyasu, M.; Osamura, A.; Ohara, M.; Yamamoto, T.; Ito, Y.; Hirano, T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. Cardiovasc. Diabetol., 2017, 16(1), 8.
[http://dx.doi.org/10.1186/s12933-016-0491-5] [PMID: 28086872]
[139]
Milonas, D.; Tziomalos, K. Sodium-glucose cotransporter 2 inhibitors and ischemic stroke. Cardiovasc. Hematol. Disord. Drug Targets, 2018, 18(2), 134-138.
[http://dx.doi.org/10.2174/1871529X18666180206120444] [PMID: 29412119]
[140]
Li, D.; Wu, T.; Wang, T.; Wei, H.; Wang, A.; Tang, H. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiol. Drug Saf., 2020, 29(5), 582-590.
[http://dx.doi.org/10.1002/pds.4985]
[141]
Chen, L.H.; Leung, P.S. Inhibition of the sodium glucose co-transporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes. Metab., 2013, 15(5), 392-402.
[http://dx.doi.org/10.1111/dom.12064] [PMID: 23331516]
[142]
Ferrannini, E.; Muscelli, E.; Frascerra, S.; Baldi, S.; Mari, A.; Heise, T.; Broedl, U.C.; Woerle, H.J. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest., 2014, 124(2), 499-508.
[http://dx.doi.org/10.1172/JCI72227] [PMID: 24463454]
[143]
Kullmann, S.; Hummel, J.; Wagner, R.; Dannecker, C.; Vosseler, A.; Fritsche, L. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care, 2022, 45(2), 398-406.
[144]
Sumida, Y.; Yoneda, M.; Tokushige, K.; Kawanaka, M.; Fujii, H.; Yoneda, M.; Imajo, K. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int. J. Mol. Sci., 2020, 21(6), 1907.
[145]
Jung, C.H.; Mok, J.O. The effects of hypoglycemic agents on non-alcoholic fatty liver disease: Focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J. Obes. Metab. Syndr., 2019, 28(1), 18-29.
[http://dx.doi.org/10.7570/jomes.2019.28.1.18] [PMID: 31089576]
[146]
Cho, K.Y.; Nakamura, A. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J. Diabetes Investig., 2021, 12(7), 1272-1277.
[http://dx.doi.org/10.1111/jdi.13457]
[147]
Kuchay, M.S.; Krishan, S.; Mishra, S.K.; Farooqui, K.J.; Singh, M.K.; Wasir, J.S.; Bansal, B.; Kaur, P.; Jevalikar, G.; Gill, H.K.; Choudhary, N.S.; Mithal, A. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial). Diabetes Care, 2018, 41(8), 1801-1808.
[http://dx.doi.org/10.2337/dc18-0165] [PMID: 29895557]
[148]
Wong, C.; Yaow, C.Y.L.; Ng, C.H.; Chin, Y.H.; Low, Y.F.; Lim, A.Y.L.; Muthiah, M.D.; Khoo, C.M. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: A meta-analysis. Front. Endocrinol., 2021, 11, 609135.
[http://dx.doi.org/10.3389/fendo.2020.609135] [PMID: 33643221]
[149]
Mantovani, A.; Petracca, G.; Csermely, A.; Beatrice, G.; Targher, G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Metabolites, 2020, 11(1), 22.
[http://dx.doi.org/10.3390/metabo11010022]
[150]
Lopaschuk, G.D.; Verma, S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl. Sci., 2020, 5(6), 632-644.
[http://dx.doi.org/10.1016/j.jacbts.2020.02.004] [PMID: 32613148]
[151]
Mazidi, M.; Rezaie, P.; Gao, H.K.; Kengne, A.P. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J. Am. Heart Assoc., 2017, 6(6), e004007.
[http://dx.doi.org/10.1161/JAHA.116.004007] [PMID: 28546454]
[152]
Ferrannini, E.; Baldi, S.; Frascerra, S.; Astiarraga, B.; Barsotti, E.; Clerico, A.; Muscelli, E. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care, 2017, 40(6), 771-776.
[http://dx.doi.org/10.2337/dc16-2724] [PMID: 28325783]
[153]
Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab., 2013, 15(9), 853-862.
[http://dx.doi.org/10.1111/dom.12127] [PMID: 23668478]
[154]
Hallow, K.M.; Helmlinger, G.; Greasley, P.J.; McMurray, J.J.V. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes. Metab., 2018, 20(3), 479-487.
[155]
Ghanim, H.; Batra, M.; Green, K.; Hejna, J.; Abuaysheh, S.; Makdissi, A.; Chaudhuri, A.; Dandona, P. Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. Diabetes Obes. Metab., 2021, 23(7), 1614-1623.
[http://dx.doi.org/10.1111/dom.14377]
[156]
Lopaschuk, G.D.; Ussher, J.R.; Folmes, C.D.L.; Jaswal, J.S.; Stanley, W.C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev., 2010, 90(1), 207-258.
[http://dx.doi.org/10.1152/physrev.00015.2009] [PMID: 20086077]
[157]
Zhang, L.; Jaswal, J.S.; Ussher, J.R.; Sankaralingam, S.; Wagg, C.; Zaugg, M.; Lopaschuk, G.D. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail., 2013, 6(5), 1039-1048.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000228] [PMID: 23861485]
[158]
Wen, J.; Wang, J.; Guo, L.; Cai, W.; Wu, Y.; Chen, W.; Tang, X. Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats. Am. J. Transl. Res., 2019, 11(3), 1327-1342.
[PMID: 30972165]
[159]
Mori, J.; Basu, R.; McLean, B.A.; Das, S.K.; Zhang, L.; Patel, V.B.; Wagg, C.S.; Kassiri, Z.; Lopaschuk, G.D.; Oudit, G.Y. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: A metabolic contribution to heart failure with normal ejection fraction. Circ. Heart Fail., 2012, 5(4), 493-503.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.966705] [PMID: 22705769]
[160]
Neubauer, S. The failing heart-an engine out of fuel. N. Engl. J. Med., 2007, 356(11), 1140-1151.
[http://dx.doi.org/10.1056/NEJMra063052] [PMID: 17360992]
[161]
AbouEzzeddine, O.F.; Kemp, B.J.; Borlaug, B.A.; Mullan, B.P.; Behfar, A.; Pislaru, S.V.; Fudim, M.; Redfield, M.M.; Chareonthaitawee, P. Myocardial energetics in heart failure with preserved ejection fraction. Circ. Heart Fail., 2019, 12(10), e006240.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006240] [PMID: 31610726]
[162]
Al Jobori, H.; Daniele, G.; Adams, J.; Cersosimo, E.; Triplitt, C.; DeFronzo, R.A.; Abdul-Ghani, M. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab., 2017, 19(6), 809-813.
[163]
Ferrannini, E.; Baldi, S.; Frascerra, S.; Astiarraga, B.; Heise, T.; Bizzotto, R.; Mari, A.; Pieber, T.R.; Muscelli, E. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes, 2016, 65(5), 1190-1195.
[http://dx.doi.org/10.2337/db15-1356] [PMID: 26861783]
[164]
Mudaliar, S.; Alloju, S.; Henry, R.R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care, 2016, 39(7), 1115-1122.
[http://dx.doi.org/10.2337/dc16-0542] [PMID: 27289124]
[165]
Ferrannini, E.; Mark, M.; Mayoux, E. CV Protection in the EMPA-REG OUTCOME trial: A “Thrifty Substrate” Hypothesis. Diabetes Care, 2016, 39(7), 1108-1114.
[http://dx.doi.org/10.2337/dc16-0330] [PMID: 27289126]
[166]
Lopaschuk, G.D.; Verma, S. Empagliflozin’s fuel hypothesis: Not so soon. Cell Metab., 2016, 24(2), 200-202.
[http://dx.doi.org/10.1016/j.cmet.2016.07.018] [PMID: 27508868]
[167]
Ho, K.L.; Zhang, L.; Wagg, C.; Al Batran, R.; Gopal, K.; Levasseur, J.; Leone, T.; Dyck, J.R.B.; Ussher, J.R.; Muoio, D.M.; Kelly, D.P.; Lopaschuk, G.D. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc. Res., 2019, 115(11), 1606-1616.
[http://dx.doi.org/10.1093/cvr/cvz045] [PMID: 30778524]
[168]
Bedi, K.C., Jr; Snyder, N.W.; Brandimarto, J.; Aziz, M.; Mesaros, C.; Worth, A.J.; Wang, L.L.; Javaheri, A.; Blair, I.A.; Margulies, K.B.; Rame, J.E. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation, 2016, 133(8), 706-716.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017545] [PMID: 26819374]
[169]
Aubert, G.; Martin, O.J.; Horton, J.L.; Lai, L.; Vega, R.B.; Leone, T.C.; Koves, T.; Gardell, S.J.; Krüger, M.; Hoppel, C.L.; Lewandowski, E.D.; Crawford, P.A.; Muoio, D.M.; Kelly, D.P. The failing heart relies on ketone bodies as a fuel. Circulation, 2016, 133(8), 698-705.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017355] [PMID: 26819376]
[170]
Horton, J.L.; Davidson, M.T.; Kurishima, C.; Vega, R.B.; Powers, J.C.; Matsuura, T.R.; Petucci, C.; Lewandowski, E.D.; Crawford, P.A.; Muoio, D.M.; Recchia, F.A.; Kelly, D.P. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight, 2019, 4(4), e124079.
[http://dx.doi.org/10.1172/jci.insight.124079] [PMID: 30668551]
[171]
Verma, S.; Rawat, S.; Ho, K.L.; Wagg, C.S.; Zhang, L.; Teoh, H.; Dyck, J.E.; Uddin, G.M.; Oudit, G.Y.; Mayoux, E.; Lehrke, M.; Marx, N.; Lopaschuk, G.D. Empagliflozin increases cardiac energy production in diabetes. JACC Basic Transl. Sci., 2018, 3(5), 575-587.
[http://dx.doi.org/10.1016/j.jacbts.2018.07.006] [PMID: 30456329]
[172]
Nielsen, R.; Møller, N.; Gormsen, L.C.; Tolbod, L.P.; Hansson, N.H.; Sorensen, J.; Harms, H.J.; Frøkiær, J.; Eiskjaer, H.; Jespersen, N.R.; Mellemkjaer, S.; Lassen, T.R.; Pryds, K.; Bøtker, H.E.; Wiggers, H. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation, 2019, 139(18), 2129-2141.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036459] [PMID: 30884964]
[173]
Zhou, B.; Tian, R. Mitochondrial dysfunction in pathophysiology of heart failure. J. Clin. Invest., 2018, 128(9), 3716-3726.
[http://dx.doi.org/10.1172/JCI120849] [PMID: 30124471]
[174]
Li, C.; Zhang, J.; Xue, M.; Li, X.; Han, F.; Liu, X.; Xu, L.; Lu, Y.; Cheng, Y.; Li, T.; Yu, X.; Sun, B.; Chen, L. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol., 2019, 18(1), 15.
[http://dx.doi.org/10.1186/s12933-019-0816-2] [PMID: 30710997]
[175]
Dick, S.A.; Epelman, S. Chronic heart failure and inflammation. Circ. Res., 2016, 119(1), 159-176.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.308030] [PMID: 27340274]
[176]
Mehta, J.L.; Pothineni, N.V. Inflammation in heart failure: The holy grail? Hypertension, 2016, 68(1), 27-29.
[177]
Briasoulis, A.; Androulakis, E.; Christophides, T.; Tousoulis, D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail. Rev., 2016, 21(2), 169-176.
[http://dx.doi.org/10.1007/s10741-016-9533-z] [PMID: 26872673]
[178]
Heerspink, H.J.L.; Perco, P.; Mulder, S.; Leierer, J.; Hansen, M.K.; Heinzel, A.; Mayer, G. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia, 2019, 62(7), 1154-1166.
[http://dx.doi.org/10.1007/s00125-019-4859-4] [PMID: 31001673]
[179]
Iannantuoni, F. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J. Clin. Med., 2019, 8(11), 1814.
[180]
Leng, W.; Wu, M.; Pan, H.; Lei, X.; Chen, L.; Wu, Q.; Ouyang, X.; Liang, Z. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann. Transl. Med., 2019, 7(18), 429.
[http://dx.doi.org/10.21037/atm.2019.09.03] [PMID: 31700865]
[181]
Lee, T.M.; Chang, N.C.; Lin, S.Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med., 2017, 104, 298-310.
[http://dx.doi.org/10.1016/j.freeradbiomed.2017.01.035] [PMID: 28132924]
[182]
Kang, S.; Verma, S.; Hassanabad, A.F.; Teng, G.; Belke, D.D.; Dundas, J.A.; Guzzardi, D.G.; Svystonyuk, D.A.; Pattar, S.S.; Park, D.S.J.; Turnbull, J.D.; Duff, H.J.; Tibbles, L.A.; Cunnington, R.H.; Dyck, J.R.B.; Fedak, P.W.M. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: Novel translational clues to explain empa-reg outcome results. Can. J. Cardiol., 2020, 36(4), 543-553.
[http://dx.doi.org/10.1016/j.cjca.2019.08.033] [PMID: 31837891]
[183]
Grubić Rotkvić, P.; Cigrovski Berković, M.; Bulj, N.; Rotkvić, L. Minireview: Are SGLT2 inhibitors heart savers in diabetes? Heart Fail. Rev., 2020, 25(6), 899-905.
[http://dx.doi.org/10.1007/s10741-019-09849-3] [PMID: 31410757]
[184]
Butts, B.; Gary, R.A.; Dunbar, S.B.; Butler, J. The importance of nlrp3 inflammasome in heart failure. J. Card. Fail., 2015, 21(7), 586-593.
[http://dx.doi.org/10.1016/j.cardfail.2015.04.014] [PMID: 25982825]
[185]
Lee, Y.H.; Kim, S.R.; Han, D.H.; Yu, H.T.; Han, Y.D.; Kim, J.H.; Kim, S.H.; Lee, C.J. Senescent T cells predict the development of hyperglycemia in humans. Diabetes, 2019, 68(1), 156-162.
[http://dx.doi.org/10.2337/db17-1218]
[186]
Tahara, A.; Kurosaki, E.; Yokono, M.; Yamajuku, D.; Kihara, R.; Hayashizaki, Y.; Takasu, T.; Imamura, M.; Li, Q.; Tomiyama, H.; Kobayashi, Y.; Noda, A.; Sasamata, M.; Shibasaki, M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol., 2013, 715(1-3), 246-255.
[http://dx.doi.org/10.1016/j.ejphar.2013.05.014] [PMID: 23707905]
[187]
Benetti, E.; Mastrocola, R.; Vitarelli, G.; Cutrin, J.C.; Nigro, D.; Chiazza, F.; Mayoux, E.; Collino, M.; Fantozzi, R. Empagliflozin protects against diet-induced nlrp-3 inflammasome activation and lipid accumulation. J. Pharmacol. Exp. Ther., 2016, 359(1), 45-53.
[http://dx.doi.org/10.1124/jpet.116.235069] [PMID: 27440421]
[188]
Ye, Y.; Jia, X.; Bajaj, M.; Birnbaum, Y. Dapagliflozin attenuates Na(+)/H(+) exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc. Drugs Ther., 2018, 32(6), 553-558.
[189]
Byrne, N.J.; Matsumura, N.; Maayah, Z.H.; Ferdaoussi, M.; Takahara, S.; Darwesh, A.M.; Levasseur, J.L.; Jahng, J.W.S.; Vos, D.; Parajuli, N.; El-Kadi, A.O.S.; Braam, B.; Young, M.E.; Verma, S.; Light, P.E.; Sweeney, G.; Seubert, J.M.; Dyck, J.R.B. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) inflammasome activation in heart failure. Circ. Heart Fail., 2020, 13(1), e006277.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.119.006277] [PMID: 31957470]
[190]
Youm, Y.H.; Nguyen, K.Y.; Grant, R.W.; Goldberg, E.L.; Bodogai, M.; Kim, D.; D’Agostino, D.; Planavsky, N.; Lupfer, C.; Kanneganti, T.D.; Kang, S.; Horvath, T.L.; Fahmy, T.M.; Crawford, P.A.; Biragyn, A.; Alnemri, E.; Dixit, V.D. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat. Med., 2015, 21(3), 263-269.
[http://dx.doi.org/10.1038/nm.3804] [PMID: 25686106]
[191]
Connelly, K.A.; Zhang, Y.; Visram, A.; Advani, A.; Batchu, S.N.; Desjardins, J.F.; Thai, K.; Gilbert, R.E. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl. Sci., 2019, 4(1), 27-37.
[http://dx.doi.org/10.1016/j.jacbts.2018.11.010] [PMID: 30847416]
[192]
Byrne, N.J.; Parajuli, N.; Levasseur, J.L.; Boisvenue, J.; Beker, D.L.; Masson, G.; Fedak, P.W.M.; Verma, S.; Dyck, J.R.B. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl. Sci., 2017, 2(4), 347-354.
[http://dx.doi.org/10.1016/j.jacbts.2017.07.003] [PMID: 30062155]
[193]
Shi, L.; Zhu, D.; Wang, S.; Jiang, A.; Li, F. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am. J. Hypertens., 2019, 32(5), 452-459.
[http://dx.doi.org/10.1093/ajh/hpz016] [PMID: 30689697]
[194]
Verma, S.; Garg, A.; Yan, A.T.; Gupta, A.K.; Al-Omran, M.; Sabongui, A.; Teoh, H.; Mazer, C.D.; Connelly, K.A. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: An important clue to the EMPA-REG OUTCOME trial? Diabetes Care, 2016, 39(12), e212-e213.
[http://dx.doi.org/10.2337/dc16-1312] [PMID: 27679584]
[195]
Esterline, R.L.; Vaag, A.; Oscarsson, J.; Vora, J. Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism? Eur. J. Endocrinol., 2018, 178(4), R113-R125.
[http://dx.doi.org/10.1530/EJE-17-0832] [PMID: 29371333]
[196]
Lee, H.C.; Shiou, Y.L.; Jhuo, S.J.; Chang, C.Y.; Liu, P.L.; Jhuang, W.J.; Dai, Z.K.; Chen, W.Y.; Chen, Y.F.; Lee, A.S. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc. Diabetol., 2019, 18(1), 45.
[http://dx.doi.org/10.1186/s12933-019-0849-6]
[197]
Lim, V.G.; Bell, R.M.; Arjun, S.; Kolatsi-Joannou, M.; Long, D.A.; Yellon, D.M. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl. Sci., 2019, 4(1), 15-26.
[http://dx.doi.org/10.1016/j.jacbts.2018.10.002] [PMID: 30847415]
[198]
Raggi, P.; Gadiyaram, V.; Zhang, C.; Chen, Z.; Lopaschuk, G.; Stillman, A.E. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering: A potential pleiotropic effect. J. Am. Heart Assoc., 2019, 8(12), e013104.
[http://dx.doi.org/10.1161/JAHA.119.013104] [PMID: 31190609]
[199]
Iborra-Egea, O.; Santiago-Vacas, E.; Yurista, S.R.; Lupón, J.; Packer, M.; Heymans, S.; Zannad, F.; Butler, J.; Pascual-Figal, D.; Lax, A.; Núñez, J.; de Boer, R.A.; Bayés-Genís, A. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl. Sci., 2019, 4(7), 831-840.
[http://dx.doi.org/10.1016/j.jacbts.2019.07.010] [PMID: 31998851]
[200]
Sato, T.; Aizawa, Y.; Yuasa, S.; Kishi, S.; Fuse, K.; Fujita, S.; Ikeda, Y.; Kitazawa, H.; Takahashi, M.; Sato, M.; Okabe, M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc. Diabetol., 2018, 17(1), 6.
[http://dx.doi.org/10.1186/s12933-017-0658-8] [PMID: 29301516]
[201]
Chan, M.C.Y.; Chan, J.C.H. Novel drugs for diabetes also have dramatic benefits on hard outcomes of heart and kidney disease. Curr. Cardiol. Rev., 2022, 18(6), e110522204572.
[http://dx.doi.org/10.2174/1573403X18666220511114443] [PMID: 35546744]
[202]
McDonald, M.; Virani, S.; Chan, M.; Ducharme, A.; Ezekowitz, J.A.; Giannetti, N.; Heckman, G.A.; Howlett, J.G.; Koshman, S.L.; Lepage, S.; Mielniczuk, L.; Moe, G.W.; O’Meara, E.; Swiggum, E.; Toma, M.; Zieroth, S.; Anderson, K.; Bray, S.A.; Clarke, B.; Cohen-Solal, A.; D’Astous, M.; Davis, M.; De, S.; Grant, A.D.M.; Grzeslo, A.; Heshka, J.; Keen, S.; Kouz, S.; Lee, D.; Masoudi, F.A.; McKelvie, R.; Parent, M.C.; Poon, S.; Rajda, M.; Sharma, A.; Siatecki, K.; Storm, K.; Sussex, B.; Van Spall, H.; Yip, A.M.C. CCS/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can. J. Cardiol., 2021, 37(4), 531-546.
[http://dx.doi.org/10.1016/j.cjca.2021.01.017] [PMID: 33827756]
[203]
Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; Fang, J.C.; Fedson, S.E.; Fonarow, G.C.; Hayek, S.S.; Hernandez, A.F.; Khazanie, P.; Kittleson, M.M.; Lee, C.S.; Link, M.S.; Milano, C.A.; Nnacheta, L.C.; Sandhu, A.T.; Stevenson, L.W.; Vardeny, O.; Vest, A.R.; Yancy, C.W. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation, 2022, 145(18), e895-e1032.
[http://dx.doi.org/10.1161/CIR.0000000000001063] [PMID: 35363499]
[204]
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int., 2022, 102(5S), S1-S127.
[PMID: 36272764]
[205]
NICE Guideline. Type 2 diabetes in adults: Management; National Institute for Health and Care Excellence (NICE), 2015.
[206]
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int., 2020, 98(4S), S1-S115.
[PMID: 32998798]
[207]
Chen, M.; Xie, C.G.; Gao, H.; Zheng, H.; Chen, Q.; Fang, J.Q. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis: Table 1. BMJ Open, 2016, 6(1), e010252.
[http://dx.doi.org/10.1136/bmjopen-2015-010252] [PMID: 26826156]
[208]
Mascolo, A.; Di Napoli, R.; Balzano, N.; Cappetta, D.; Urbanek, K.; De Angelis, A.; Scisciola, L.; Di Meo, I.; Sullo, M.G.; Rafaniello, C.; Sportiello, L. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front. Cardiovasc. Med., 2022, 9, 1010693.
[http://dx.doi.org/10.3389/fcvm.2022.1010693] [PMID: 36211584]
[209]
Chan, J.C.H.; Chan, M.C.Y. SGLT2 Inhibitors: The next blockbuster multifaceted drug? Medicina, 2023, 59(2), 388.
[http://dx.doi.org/10.3390/medicina59020388] [PMID: 36837589]
[210]
AlKindi, F.; Al-Omary, H.L.; Hussain, Q.; Al Hakim, M.; Chaaban, A.; Boobes, Y. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant. Proc., 2020, 52(1), 175-178.
[http://dx.doi.org/10.1016/j.transproceed.2019.11.007] [PMID: 31924404]
[211]
Hecking, M.; Jenssen, T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat. Rev. Nephrol., 2019, 15(9), 525-526.
[http://dx.doi.org/10.1038/s41581-019-0173-0] [PMID: 31235880]
[212]
Loutradis, C.; Papadopoulou, E.; Theodorakopoulou, M.; Karagiannis, A.; Sarafidis, P. The effect of SGLT-2 inhibitors on blood pressure: A pleiotropic action favoring cardio- and nephroprotection. Future Med. Chem., 2019, 11(11), 1285-1303.
[http://dx.doi.org/10.4155/fmc-2018-0514] [PMID: 31161798]
[213]
Harrington, J.; Udell, J.A.; Jones, W.S.; Anker, S.D.; Bhatt, D.L.; Petrie, M.C.; Vedin, O.; Sumin, M.; Zwiener, I.; Hernandez, A.F.; Butler, J. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am. Heart J., 2022, 253, 86-98.
[http://dx.doi.org/10.1016/j.ahj.2022.05.010] [PMID: 35595091]
[214]
He, X.; Gao, X.; Xie, P.; Liu, Y.; Bai, W.; Liu, Y.; Shi, A. Pharmacokinetics, pharmacodynamics, safety and tolerability of sotagliflozin after multiple ascending doses in chinese healthy subjects. Drug Des. Devel. Ther., 2022, 16, 2967-2980.
[http://dx.doi.org/10.2147/DDDT.S372575] [PMID: 36097559]
[215]
Huh, Y.; Kim, Y.S. Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Primary Care, 2022, 23(1), 134.
[216]
Anderson, S.L. Dapagliflozin efficacy and safety: A perspective review. Ther. Adv. Drug Saf., 2014, 5(6), 242-254.
[http://dx.doi.org/10.1177/2042098614551938] [PMID: 25436106]
[217]
Mosenzon, O.; Wiviott, S.D.; Heerspink, H.J.L. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44(8), 1085-1815.
[218]
Sjöström, C.D.; Johansson, P.; Ptaszynska, A.; List, J.; Johnsson, E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab. Vasc. Dis. Res., 2015, 12(5), 352-358.
[http://dx.doi.org/10.1177/1479164115585298] [PMID: 26008804]
[219]
McDowell, K.; Welsh, P.; Docherty, K.F.; Morrow, D.A.; Jhund, P.S.; de Boer, R.A.; O’Meara, E.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Hammarstedt, A.; Langkilde, A.M.; Sjöstrand, M.; Lindholm, D.; Solomon, S.D.; Sattar, N.; Sabatine, M.S.; McMurray, J.J.V. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur. J. Heart Fail., 2022, 24(6), 1066-1076.
[http://dx.doi.org/10.1002/ejhf.2433] [PMID: 35064721]
[220]
McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; Böhm, M.; Chiang, C.E.; Chopra, V.K.; de Boer, R.A.; Desai, A.S.; Diez, M.; Drozdz, J.; Dukát, A.; Ge, J.; Howlett, J.G.; Katova, T.; Kitakaze, M.; Ljungman, C.E.A.; Merkely, B.; Nicolau, J.C.; O’Meara, E.; Petrie, M.C.; Vinh, P.N.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.L.; Docherty, K.F. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl. J. Med., 2019, 381(21), 1995-2008.
[221]
Blonde, L.; Stenlöf, K.; Fung, A.; Xie, J.; Canovatchel, W.; Meininger, G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad. Med., 2016, 128(4), 371-380.
[http://dx.doi.org/10.1080/00325481.2016.1169894] [PMID: 27002421]
[222]
Geng, Q.; Hou, F.; Zhang, Y.; Wang, Z.; Zhao, M. Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: A meta-analysis. J. Hypertens., 2022, 40(5), 996-1001.
[http://dx.doi.org/10.1097/HJH.0000000000003106] [PMID: 35221325]
[223]
Schernthaner, G.; Lavalle-González, F.J.; Davidson, J.A.; Jodon, H.; Vijapurkar, U.; Qiu, R.; Canovatchel, W. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgrad. Med., 2016, 128(8), 725-730.
[http://dx.doi.org/10.1080/00325481.2016.1210988] [PMID: 27391951]
[224]
Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Li, Q.; Jardine, M.; Oh, R.; Heerspink, H.L.; Perkovic, V. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS Program. J. Am. Soc. Nephrol., 2019, 30(11), 2229-2242.
[http://dx.doi.org/10.1681/ASN.2019010064] [PMID: 31530577]
[225]
Weir, M.R.; Januszewicz, A.; Gilbert, R.E.; Vijapurkar, U.; Kline, I.; Fung, A.; Meininger, G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J. Clin. Hypertens., 2014, 16(12), 875-882.
[http://dx.doi.org/10.1111/jch.12425] [PMID: 25329038]
[226]
Valentine, V.; Hinnen, D. Clinical implications of canagliflozin treatment in patients with type 2 diabetes. Clin. Diabetes, 2015, 33(1), 5-13.
[227]
Davies, M.J.; Trujillo, A.; Vijapurkar, U.; Damaraju, C.V.; Meininger, G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2015, 17(4), 426-429.
[http://dx.doi.org/10.1111/dom.12439] [PMID: 25600248]
[228]
Spertus, J.A.; Birmingham, M.C. The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial. Nat. Med., 2022, 28(4), 809-813.
[http://dx.doi.org/10.1038/s41591-022-01703-8]
[229]
Xu, L.; Nagata, N.; Chen, G.; Nagashimada, M.; Zhuge, F.; Ni, Y.; Sakai, Y.; Kaneko, S.; Ota, T. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res. Care, 2019, 7(1), e000783.
[http://dx.doi.org/10.1136/bmjdrc-2019-000783]
[230]
Jojima, T.; Sakurai, S.; Wakamatsu, S.; Iijima, T.; Saito, M.; Tomaru, T.; Kogai, T.; Usui, I.; Aso, Y. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. Int. J. Cardiol., 2021, 331, 243-248.
[http://dx.doi.org/10.1016/j.ijcard.2021.01.063] [PMID: 33556413]
[231]
Ozcelik, S.; Celik, M.; Vural, A.; Aydin, B. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. North. Clin. Istanb., 2019, 7(2), 167-173.
[PMID: 32259039]
[232]
Borg, R.; Persson, F. Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. Ann. Transl. Med., 2017, 5(23), 478.
[http://dx.doi.org/10.21037/atm.2017.11.02] [PMID: 29285511]
[233]
Cheng, L.; Fu, Q.; Zhou, L.; Fan, Y.; Liu, F.; Fan, Y.; Zhang, X.; Lin, W.; Wu, X. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci. Rep., 2022, 12(1), 3525.
[http://dx.doi.org/10.1038/s41598-022-07395-x] [PMID: 35241720]
[234]
Al-Jobori, H.; Daniele, G.; Cersosimo, E.; Triplitt, C.; Mehta, R.; Norton, L. Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes, 2017, 66(7), 1999-2006.
[235]
Tikkanen, I.; Narko, K.; Zeller, C.; Green, A.; Salsali, A.; Broedl, U.C.; Woerle, H.J. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care, 2015, 38(3), 420-428.
[http://dx.doi.org/10.2337/dc14-1096] [PMID: 25271206]
[236]
Ferreira, J.P.; Inzucchi, S.E. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes. Metab., 2022, 24(1), 135-141.
[http://dx.doi.org/10.1111/dom.14559]
[237]
Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; Giannetti, N.; Gomez-Mesa, J.E.; Janssens, S.; Januzzi, J.L.; Gonzalez-Juanatey, J.R.; Merkely, B.; Nicholls, S.J.; Perrone, S.V.; Piña, I.L.; Ponikowski, P.; Senni, M.; Sim, D.; Spinar, J.; Squire, I.; Taddei, S.; Tsutsui, H.; Verma, S.; Vinereanu, D.; Zhang, J.; Carson, P.; Lam, C.S.P.; Marx, N.; Zeller, C.; Sattar, N.; Jamal, W.; Schnaidt, S.; Schnee, J.M.; Brueckmann, M.; Pocock, S.J.; Zannad, F.; Packer, M. Empagliflozin in heart failure with a preserved ejection fraction. N Engl. J. Med., 2021, 385(16), 1451-1461.
[238]
Heymsfield, S.B.; Raji, A.; Gallo, S.; Liu, J.; Pong, A.; Hannachi, H.; Terra, S.G. Efficacy and safety of ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. Obesity, 2020, 28(4), 724-732.
[239]
Dagogo-Jack, S.; Liu, J.; Eldor, R.; Amorin, G.; Johnson, J.; Hille, D.; Liao, Y.; Huyck, S.; Golm, G.; Terra, S.G. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo- controlled randomized study. Diabetes Obes. Metab., 2018, 20(3), 530-540.
[240]
Cherney, D.Z.I.; Charbonnel, B.; Cosentino, F.; Dagogo-Jack, S.; McGuire, D.K.; Pratley, R.; Shih, W.J.; Frederich, R.; Maldonado, M.; Pong, A.; Cannon, C.P. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: An analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64(6), 1256-1267.
[http://dx.doi.org/10.1007/s00125-021-05407-5] [PMID: 33665685]
[241]
Liu, J.; Pong, A.; Gallo, S.; Darekar, A.; Terra, S.G. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: A post hoc pooled analysis of randomized controlled trials. Cardiovasc. Diabetol., 2019, 18(1), 59.
[http://dx.doi.org/10.1186/s12933-019-0856-7] [PMID: 31064361]
[242]
Rosenstock, J.; Frias, J.; Páll, D.; Charbonnel, B.; Pascu, R.; Saur, D.; Darekar, A.; Huyck, S.; Shi, H.; Lauring, B. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes. Metab., 2018, 20(3), 520-529.
[243]
Segar, M.W.; Kolkailah, A.A. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2022, 24(9), 1829-1839.
[http://dx.doi.org/10.1111/dom.14769]
[244]
Cosentino, F.; Cannon, C.P.; Cherney, D.Z.I.; Masiukiewicz, U.; Pratley, R.; Dagogo-Jack, S.; Frederich, R.; Charbonnel, B.; Mancuso, J.; Shih, W.J.; Terra, S.G.; Cater, N.B.; Gantz, I.; McGuire, D.K. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. Circulation, 2020, 142(23), 2205-2215.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050255] [PMID: 33026243]
[245]
Patel, S.; Hickman, A.; Frederich, R.; Johnson, S.; Huyck, S.; Mancuso, J.P.; Gantz, I.; Terra, S.G. Safety of ertugliflozin in patients with type 2 diabetes mellitus: Pooled analysis of seven phase 3 randomized controlled trials. Diabetes Ther., 2020, 11(6), 1347-1367.
[http://dx.doi.org/10.1007/s13300-020-00803-3] [PMID: 32372382]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy